News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
